Jazz Pharmaceuticals JAZZ
Jazz Pharmaceuticals is a biopharmaceutical company that develops and commercializes innovative medicines in areas of high medical need, such as oncology and neuroscience. Jazz Pharmaceuticals shows solid fundamentals with a forward P/E of 9.24, an ROE of 22.11%, and revenue growth of 15.5%, supported by a promising oncology pipeline (zanidatamab) that could generate $5B in opportunities.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Jazz Pharmaceuticals is a biopharmaceutical company that develops and commercializes innovative medicines in areas of high medical need, such as oncology and neuroscience. Jazz Pharmaceuticals shows solid fundamentals with a forward P/E of 9.24, an ROE of 22.11%, and revenue growth of 15.5%, supported by a promising oncology pipeline (zanidatamab) that could generate $5B in opportunities.
Score by category
| Category | Score |
|---|---|
| Financial health | 7.7 |
| Quality / Moat | 7.7 |
| Valuation | 7.9 |
| Growth | 8.0 |
| Dividend | 1.5 |
| Momentum | 9.7 |
| Risk & Context | 8.5 |
OVERALL SCORE: 7.6/10
Context and risks
Jazz Pharmaceuticals is domiciled in Ireland, with moderate governance risk. There is no material exposure to current macro factors (rates, oil, geopolitics) directly affecting its biopharmaceutical business.
News considered in the analysis
- Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B — El potencial de mercado de $5B para zanidatamab y los ingresos oncológicos superiores a $1B son materialmente positivos, aunque la probabilidad de alcanzar el máximo potencial es incierta y parte del optimismo ya está en el precio.
- Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands — La expansión del pipeline con Ziihera refuerza las perspectivas de crecimiento a largo plazo, pero el rango de oportunidad es amplio y depende de aprobaciones y adopción en el mercado.
- Jazz Pharmaceuticals (JAZZ) Places An $820M Epilepsy Bet — La adquisición por $820M en epilepsia es una apuesta estratégica que diversifica el portafolio, pero su impacto en beneficios a corto plazo es moderado y el mercado ya lo ha asimilado parcialmente.
- Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition? — Artículo de opinión sin información nueva sobre la adquisición de Actio; no aporta datos concretos que alteren la valoración.
- ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know — Titular sobre otra empresa (ABCL), sin relevancia directa para Jazz Pharmaceuticals.
Verdict: Hold or buy on dips, given the attractive forward multiple and pipeline growth potential, although the lack of a dividend limits appeal for income investors.
Main risk: The main risk is dependence on the approval and commercial adoption of zanidatamab/Ziihera to materialize expected growth; a delay or regulatory failure could significantly impact valuation.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →